Media headlines about Eagle Pharmaceuticals (NASDAQ:EGRX) have been trending somewhat positive on Saturday, according to Accern Sentiment. The research group scores the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Eagle Pharmaceuticals earned a news sentiment score of 0.16 on Accern’s scale. Accern also gave media stories about the specialty pharmaceutical company an impact score of 45.4277328725547 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the news articles that may have effected Accern Sentiment Analysis’s rankings:
- Barron’s After Hours: Splunk Surges, 21st Century Fox Jumps, Eagle Pharmaceuticals Plunges (barrons.com)
- Barron’s After Hours: Splunk Surges, 21st Century Fox Jumps, Eagle Pharmaceuticals Plunges (finance.yahoo.com)
- FY2018 EPS Estimates for Eagle Pharmaceuticals, Inc. (EGRX) Raised by Analyst (americanbankingnews.com)
- Eagle Pharmaceuticals, Inc. – Value Analysis (NASDAQ:EGRX) : November 10, 2017 – Investing.com (investing.com)
EGRX has been the subject of a number of analyst reports. ValuEngine raised shares of Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, October 2nd. Royal Bank Of Canada reissued an “outperform” rating and issued a $75.00 price objective (down from $81.00) on shares of Eagle Pharmaceuticals in a research report on Thursday, November 9th. BidaskClub raised shares of Eagle Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 12th. Piper Jaffray Companies reissued a “buy” rating and issued a $75.00 price objective on shares of Eagle Pharmaceuticals in a research report on Friday, October 27th. Finally, Mizuho decreased their price objective on shares of Eagle Pharmaceuticals from $57.00 to $40.00 and set an “underperform” rating for the company in a research report on Thursday, July 27th. Three investment analysts have rated the stock with a sell rating and three have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $62.33.
Eagle Pharmaceuticals (NASDAQ EGRX) traded up $0.42 during trading hours on Friday, reaching $57.40. 191,539 shares of the company’s stock were exchanged, compared to its average volume of 330,190. The company has a current ratio of 5.30, a quick ratio of 5.15 and a debt-to-equity ratio of 0.26. The stock has a market cap of $856.50, a PE ratio of 8.70 and a beta of 1.23. Eagle Pharmaceuticals has a one year low of $45.05 and a one year high of $97.15.
Eagle Pharmaceuticals declared that its Board of Directors has approved a stock repurchase program on Wednesday, August 9th that authorizes the company to buyback $100.00 million in outstanding shares. This buyback authorization authorizes the specialty pharmaceutical company to reacquire up to 13.3% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s board believes its stock is undervalued.
About Eagle Pharmaceuticals
Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.
What are top analysts saying about Eagle Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Eagle Pharmaceuticals Inc. and related companies.